Comparative Pharmacology
Head-to-head clinical analysis: ALA SCALP versus POHERDY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA SCALP versus POHERDY.
ALA-SCALP vs POHERDY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (PpIX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), PpIX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.
POHERDY is a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), binding to domain IV of the extracellular segment, thereby inhibiting ligand-independent HER2 signaling and mediating antibody-dependent cellular cytotoxicity (ADCC).
Topical application of a 5% solution to the scalp twice daily.
POHERDY: No approved drug. No dosing available.
None Documented
None Documented
Not applicable; topical ALA-SCALP is not significantly absorbed systemically. After systemic absorption from photodynamic therapy, terminal half-life is approximately 1 hour due to rapid metabolism.
Terminal half-life 12–18 hours (mean 15 h); requires dose adjustment in renal impairment (CrCl <30 mL/min)
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion is negligible.
Renal: 60% unchanged; fecal/biliary: 30%; 10% metabolized
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid